A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Open Access
- 1 September 2000
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 83 (5), 588-593
- https://doi.org/10.1054/bjoc.2000.1316
Abstract
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research CampaignKeywords
This publication has 23 references indexed in Scilit:
- Practical guidelines for the treatment of malignant gliomas.1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failureNeurology, 1990
- Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicityCancer Chemotherapy and Pharmacology, 1990
- Measurement of health status: Ascertaining the minimal clinically important differenceControlled Clinical Trials, 1989
- Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumorsCancer, 1989
- Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.1987
- Pathologic Analysis of Primary Brain TumorsNeurologic Clinics, 1985
- Procarbazine hydrochloride in the treatment of brain tumorsJournal of Neurosurgery, 1974